These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28447486)

  • 1. Guidance to develop individual dose recommendations for patients on chronic hemodialysis.
    Gotta V; Dao K; Rodieux F; Buclin T; Livio F; Pfister M
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):737-752. PubMed ID: 28447486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.
    Lalonde RL; Wagner JA
    Clin Pharmacol Ther; 2009 Nov; 86(5):557-61. PubMed ID: 19776736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.
    Tortorici MA; Cutler DL; Hazra A; Nolin TD; Rowland-Yeo K; Venkatakrishnan K
    J Clin Pharmacol; 2015 Mar; 55(3):241-50. PubMed ID: 25501531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.
    Paglialunga S; Offman E; Ichhpurani N; Marbury TC; Morimoto BH
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):273-283. PubMed ID: 27998190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.
    Smit C; De Hoogd S; Brüggemann RJM; Knibbe CAJ
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):275-285. PubMed ID: 29431542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting guidelines for population pharmacokinetic analyses.
    Dykstra K; Mehrotra N; Tornøe CW; Kastrissios H; Patel B; Al-Huniti N; Jadhav P; Wang Y; Byon W
    J Clin Pharmacol; 2015 Aug; 55(8):875-87. PubMed ID: 26148467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
    Velenosi TJ; Urquhart BL
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.
    Brussee JM; Calvier EA; Krekels EH; Välitalo PA; Tibboel D; Allegaert K; Knibbe CA
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1235-44. PubMed ID: 27269200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Informed Dose Optimization in Pregnancy.
    Chaphekar N; Caritis S; Venkataramanan R
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S63-S76. PubMed ID: 33205432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.
    Himebauch AS; Kilbaugh TJ; Zuppa AF
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1133-42. PubMed ID: 27322360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying the Effectiveness of Dose Individualization by Simulation for a Drug With Moderate Pharmacokinetic Variability.
    Liefaard L; Chen C
    Ther Drug Monit; 2015 Oct; 37(5):641-8. PubMed ID: 26378372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic concepts revisited--basic and applied.
    Patel K; Kirkpatrick CM
    Curr Pharm Biotechnol; 2011 Dec; 12(12):1983-90. PubMed ID: 21554220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.
    Zhang L; Boulton DW; Pfister M
    J Clin Pharmacol; 2012 Jan; 52(1 Suppl):126S-33S. PubMed ID: 22232748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Critique of Pharmacokinetic Calculators for Drug Dosing Individualization.
    Janković SM
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):157-162. PubMed ID: 31773426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of pharmacokinetic studies in critically ill patients receiving continuous renal replacement therapy.
    Vaara S; Pettila V; Kaukonen KM
    Acta Anaesthesiol Scand; 2012 Feb; 56(2):147-57. PubMed ID: 22092254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reporting guidelines for population pharmacokinetic analyses.
    Dykstra K; Mehrotra N; Tornøe CW; Kastrissios H; Patel B; Al-Huniti N; Jadhav P; Wang Y; Byon W
    J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):301-14. PubMed ID: 25925797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic studies in hemodialysis patients.
    Atkinson AJ; Umans JG
    Clin Pharmacol Ther; 2009 Nov; 86(5):548-52. PubMed ID: 19675540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.